| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Polyporusterone C targets cancer cells, specifically L-1210 cells. It exhibits cytotoxic activity. Its mechanism may involve induction of apoptosis or disruption of cell cycle progression in cancer cells. It is a naturally occurring compound with antitumor potential.
|
|---|---|
| ln Vitro |
In vitro, Polyporusterone C shows cytotoxic activities against L-1210 cells with IC50 values of 37, 26, and 42 μg/mL at 3, 5, and 7 days, respectively. It is a natural product isolated from Polyporus umbellatus. It exhibits antitumor activity.
|
| ln Vivo |
In vivo, Polyporusterone C has potential antitumor activity based on its in vitro cytotoxicity. Animal studies are needed to confirm its in vivo efficacy and safety. Its natural source, Polyporus umbellatus, is used in traditional medicine for its antitumor properties.
|
| Enzyme Assay |
Cell-free assays for Polyporusterone C: cytotoxicity is assessed using cell-free systems such as enzyme inhibition assays (e.g., topoisomerase inhibition). The compound is incubated with enzymes, and activity is measured spectrophotometrically. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Polyporusterone C: L-1210 cells or other cancer cell lines are cultured and treated with Polyporusterone C at concentrations of 0.1-100 µM for 3-7 days. Cell viability is measured by MTT or CellTiter-Glo assays. Apoptosis is assessed by Annexin V/PI staining. Cell cycle analysis is performed by propidium iodide staining.
|
| Animal Protocol |
In vivo animal studies for Polyporusterone C: xenograft mouse models of cancer would be used. Mice are implanted with cancer cells and treated with Polyporusterone C orally or intraperitoneally at doses of 10-50 mg/kg. Tumor growth, apoptosis markers, and toxicity are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Polyporusterone C: as a steroidal compound, it may have moderate oral bioavailability. It is likely metabolized in the liver. Tissue distribution and elimination pathways require further investigation. Storage: powder at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
Toxicity of Polyporusterone C: comprehensive toxicity data are limited. As a cytotoxic agent, it may have significant toxicity at high doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Reports indicate that (2S,3R,5R,9R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[(1R)-1-hydroxy-1-[(2R,3S)-3-[(2R)-3-methylbut-2-yl]ethyleneoxy-2-yl]ethyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-6-one has been discovered in the fungus Polyporus umbellatus, and related data have been reported.
Polyporusterone C is a research compound with potential applications in anticancer research. It is isolated from Polyporus umbellatus. Its mechanism involves cytotoxic activity against cancer cells. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C28H44O6
|
|---|---|
| Molecular Weight |
476.65
|
| Exact Mass |
476.313
|
| CAS # |
141360-90-9
|
| PubChem CID |
44575600
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
899
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@@H]([C@H]1[C@@H](O1)[C@@](C)([C@H]2CC[C@@]3([C@@]2(CC[C@H]4C3=CC(=O)[C@H]5[C@@]4(C[C@@H]([C@@H](C5)O)O)C)C)O)O)C(C)C
|
| InChi Key |
XOSHHFGXQBEREG-TUUJZBRNSA-N
|
| InChi Code |
InChI=1S/C28H44O6/c1-14(2)15(3)23-24(34-23)27(6,32)22-8-10-28(33)17-11-19(29)18-12-20(30)21(31)13-25(18,4)16(17)7-9-26(22,28)5/h11,14-16,18,20-24,30-33H,7-10,12-13H2,1-6H3/t15-,16+,18+,20-,21+,22+,23+,24-,25-,26-,27-,28-/m1/s1
|
| Chemical Name |
(2S,3R,5R,9R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[(1R)-1-hydroxy-1-[(2R,3S)-3-[(2R)-3-methylbutan-2-yl]oxiran-2-yl]ethyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0980 mL | 10.4899 mL | 20.9798 mL | |
| 5 mM | 0.4196 mL | 2.0980 mL | 4.1960 mL | |
| 10 mM | 0.2098 mL | 1.0490 mL | 2.0980 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
